Search clinical trials for: HCC PVTT TACE RFA

Total 2052 results

Ming Zhao

Unknown

Combine TACE and RFA Versus TACE Alone for HCC With PVTT (CORTT)

Hepatocellular Carcinoma

China
Sun Yat-sen University

Recruiting

Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial

Hepatocellular Carcinoma

China
Third Affiliated Hospital, Sun Yat-Sen University
Sun Yat-sen University; Fifth Affiliated Hospital, Sun Yat-Sen University; Second... and other collaborators

Not yet recruiting

TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Hepatocellular Carcinoma | Hepatic Portal Vein Tumor Invasion | Tumor Thrombus
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Hepatocellular Carcinoma Non-resectable

China
Sun Yat-sen University

Recruiting

Neo-TACE-HAIC for PVTT-HCC (NeoconceptC)

Hepatocellular Carcinoma | Portal Vein Thrombosis

China
Jinglong Chen

Recruiting

Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC

Hepatocellular Carcinoma

China
Second Affiliated Hospital of Guangzhou Medical...
First People's Hospital of Foshan; Huizhou Municipal Central Hospital; Zhongshan... and other collaborators

Completed

Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT

Hepatocellular Carcinoma Non-resectable

China
Institut für Klinische Krebsforschung IKF GmbH...

Active, not recruiting

IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC)

Germany
National Cancer Institute (NCI)

Completed

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Hepatocellular Carcinoma | Cholangiocarcinoma | Bile Duct Cancer | Biliary Tract Neoplasms | Liver Cancer

United States
Sun Yat-sen University

Withdrawn

Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT

Advanced Hepatocellular Carcinoma

China
Yunfei Yuan

Completed

TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT

Hepatocellular Carcinoma

China
Beijing Ditan Hospital

Enrolling by invitation

Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT

Carcinoma, Hepatocellular | Portal Vein Tumor Thrombus

China
Beijing Tsinghua Chang Gung Hospital

Unknown

Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)

Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)

China
Fudan University

Unknown

Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE

Hepatocellular Carcinoma

China
Cancer Hospital of Guangxi Medical University

Unknown

A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection

Hepatocellular Carcinoma

China
Zhongda Hospital

Unknown

Irradiation Stent Placement Plus TACE for HCC and PVTT

Hepatocellular Carcinoma | Portal Vein Tumor Thrombosis

China
Zhongda Hospital

Completed

ISP-TACE Versus TACE for HCC With PVTT

HCC | Portal Vein Tumor Thrombosis

China
Shi-Ming Lin

Unknown

Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient

Hepatocellular Carcinoma

Taiwan
Sun Yat-sen University

Unknown

Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma

Hepatocellular Carcinoma | RFA | TACE

China
Sun Yat-sen University

Unknown

Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis

Hepatocellular Carcinoma With PVTT

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

Hepatocellular Carcinoma Non-resectable

China
RenJi Hospital
Boston Scientific Corporation

Not yet recruiting

DEB-TACE Prior to Liver Transplantation in the Treatment of HCC

Liver Cancer
Yongyi Zeng

Not yet recruiting

Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT

Hepatocellular Carcinoma
Henan Cancer Hospital

Not yet recruiting

Tace With Icaritin in First-line Treatment of Middle and Advanced HCC in Child Grade B Patients

HCC
Chen Xiaoping

Recruiting

Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy.

Hepatocellular Carcinoma

China
Li Xiao Wei

Not yet recruiting

HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL) (HAI-TL)

Hepatocellular Carcinoma With PVTT

China
Zhongda Hospital

Recruiting

DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC

Hepatocellular Carcinoma

China
Zhujiang Hospital

Recruiting

CT Imaging for Guiding PA-TACE for HCC

Carcinoma, Hepatocellular

China
Tongji Hospital

Not yet recruiting

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

Hepatocellular Carcinoma

China
Assistance Publique - Hôpitaux de Paris
AstraZeneca

Recruiting

Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation (DUMELEP)

BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA

France
Zhongda Hospital

Not yet recruiting

Efficacy, Safety, and Treatment Patterns of Transcatheter Arterial Chemoembolization (TACE) Combined With Atezolizumab and Bevacizumab in Unresectable Hepatocellular Carcinoma: a Multicenter, Retrospective, Observational Real-world Study (CHANCE023)

HCC
Xuhua Duan

Not yet recruiting

A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

China
First Affiliated Hospital of Fujian Medical University

Recruiting

A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC

Hepatocellular Carcinoma Resectable

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC

Hepatocellular Carcinoma | Thrombocytopenia

China
Second Affiliated Hospital of Guangzhou Medical...
First People's Hospital of Foshan; Affiliated Cancer Hospital & Institute of... and other collaborators

Recruiting

Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
The First Affiliated Hospital of Xiamen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma | Bevacizumab | TACE | Adebrelimab | Transformation

China
Terumo Europe N.V.

Recruiting

BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC) (BIOPEARL-ONE)

Hepatocellular Carcinoma Non-resectable

Belgium, Germany, Italy
Sun Yat-sen University

Not yet recruiting

TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria (B-TACE)

Hepatocellular Carcinoma by BCLC Stage

China
Peking University Cancer Hospital & Institute

Recruiting

The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma (HCC)

China
Peking Union Medical College Hospital

Recruiting

Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC

Hepatocellular Carcinoma

China
Xuhua Duan

Recruiting

DEB-TACE Versus DEB-TACE Sequential HAIC for Unresectable BCLC Stage C HCC; A Randomized Controlled Trial

HCC

China
Yale University
Genentech, Inc.

Recruiting

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma

United States
Sun Yat-sen University

Recruiting

TACE-HAIC Plus Atezolizumab and Bevacizumab for Unresectable HCC: a Phase 2 Clinical Trial

Hepatocellular Carcinoma

China
Sun Yat-sen University

Not yet recruiting

SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH) (SEARCH)

Advanced Hepatocellular Carcinoma

China
Zhongda Hospital

Recruiting

Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301)

Hepatocellular Carcinoma | Portal Hypertension

China
Zhongda Hospital

Recruiting

CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302)

Hepatocellular Carcinoma | Portal Hypertension

China
Nadeem Iqbal
Ahmad Zia; Muhammad Junaid Tahir

Recruiting

Prophylactic Antibiotic Use in Transarterial Chemoembolization for Hepatocellular Carcinoma

Antibiotic Prophylaxis

Pakistan
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

Hepatocellular Carcinoma Non-resectable

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

Hepatocellular Carcinoma Non-resectable

China
University of Pisa
Azienda Ospedaliera Città della Salute e della Scienza di Torino; Fondazione... and other collaborators

Recruiting

Occlusafe® Assisted MW Alone or With DEB-TACE Compared to MW With DEB-TACE in the Treatment of HCC (SEASON-HCC)

HCC

Italy

Search clinical trials for: HCC PVTT TACE RFA

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations